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Antimicrobials are frequently used for empirical therapy of suspected infections,
before comfirming aetiology. The choice of empirical therapy should be guided
by current data on susceptibility patterns of bacteria that have been shown to
cause defined clinical presentations, e.g. community-acquired pneumonia (CAP)
or uncomplicated urinary tract infections. In South Africa it is essential that we
conduct our own regular studies of defined clinical syndromes to identify their
infectious causes and to evaluate their resistance profiles, as aetiology and sus-
ceptibility patterns may vary from country to country. Within South Africa, these
data may differ between regions.
There are many public, private and academic centres which collect data. For
example, different centres in the country collect a wide range of data about the
agents causing sexually transmitted infections (STIs) and their susceptibility to
antimicrobials. This guides clinicians in their choice of therapy, without the need
to take specimens from each patient for diagnosis or susceptibility testing. The
well-described syndromic approach followed in many STI clinics in South Africa,
is used in an attenuated form for many other infectious presentations: clinicians
make the diagnosis of CAP (the syndrome) and use published, anecdotal or own-
experience data to assist them in the management of this infection. Although
specimens may be submitted for microbiological evaluation of respiratory tract
infections, the yield may be disappointing.1
INTERPRETING SURVEILLANCE DATA
The purpose of surveillance is to monitor accurately the spread of resistance, and
to limit this by appropriate antimicrobial usage and infection control strategies. In
order for this to happen, surveillance data need to be returned timeously to clini-
cians and the committees that formulate treatment guidelines.2
In a study in the USA it was shown that data from a limited number of laborato-
ries, rather than from all laboratories in a state, could reliably detect large
changes in penicillin susceptibility in pneumococci. However, this did not accu-
rately reflect an area’s actual percentage of penicillin-resistant isolates.3
We are clearly seeing a high degree of variability in resistance data from labora-
tories and groups of laboratories in South Africa. This may be explained by a
number of factors that need to be kept in mind when interpreting surveillance
data (Table I).
Disc diffusion testing is the most common form of routine susceptibility testing per-
formed in diagnostic clinical laboratories. It may be adequate to guide the use of
antibiotics for some bacteria reliably (e.g. Gram-negative bacteria belonging to
the family Enterobacteriaceae, e.g. Escherichia coli). In other cases the identity of
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the organism may be sufficient to pre-
dict susceptibility to penicillin, e.g.
Streptococcus pyogenes or Strepto-
coccus agalactiae, where resistant iso-
lates have not been described.
With other organisms, such as
Streptococcus pneumoniae, additional
factors need to be kept in mind.
Oxacillin discs are used to predict
penicillin susceptibility in the laborato-
ry, as this has been found to be more
accurate than using penicillin or ampi-
cillin discs. Zone sizes read as resist-
ant on oxacillin disc testing may occur
with penicillin-resistant, intermediate or
certain susceptible strains, and there-
fore monitoring of resistance should
not be based on disc diffusion testing
alone. Clinical reporting may be suffi-
cient with this form of testing, because
if the zone sizes are at least equal to
20 mm, as determined in the laborato-
ry, the isolate can reliably be reported
as being susceptible to penicillin.
Minimum inhibitory concentration
(MIC) testing is the gold standard for
predicting susceptibility, and can be
determined by using E tests (used in
clinical diagnostic laboratories) or the
reference agar or broth dilution meth-
ods (used in academic centres or larg-
er laboratories in South Africa).
Breakpoints define the concentration
of the antimicrobial, below which the
isolate is called susceptible and above
which the isolate is determined as
resistant.
In addition to the in vitro testing of the
organism against the antimicrobial,
the site of the infection and the pene-
tration of the drug to the site must be
considered when discussing optimal
therapy (pharmacokinetic and pharma-
codynamic parameters). For example,
the breakpoints for determination of
susceptibility of pneumococci vary
depending on the site of infection.
Breakpoints for isolates from patients
with meningitis are higher than those
for pneumonia, because achievable
levels of drugs in the cerebrospinal
fluid (CSF) are less than those
achieved in the alveolar space.
RECENT DATA FOR SOUTH
AFRICAN ISOLATES
Streptococcus pneumoniae
Resistant S. pneumoniae are more com-
monly found in children, in HIV-
seropositive individuals4 and from non-
sterile isolates. Surveillance studies
should ideally report according to
specimen source and patient age, and
discuss details of the patient popula-
tion and their clinical presentations.
Cerebrospinal fluid isolates
Over a period of 12 months (August
2001 - July 2002), 101 of 526
viable isolates (19%) (including 9 from
the private sector) from CSF were
intermediately resistant to penicillin,
and 2 (0.4%) were high-level resistant.
These were taken mainly from the pub-
lic sector. None of these 526 isolates
was resistant to cephalosporins on
MIC testing (Anne von Gottberg —
unpublished data). Recent data from
private laboratories in Johannesburg
have shown an increase in the number
of pneumococci isolated from CSF that
are resistant to third-generation
cephalosporins: 25% of 14 isolates
during a 6-month period from July
2002 to December 2002 (Adrian
Brink and the Antibiotic Surveillance
Forum, ASF — personal communica-
tion).
Empirical therapy of meningitis with
ceftriaxone or cefotaxime covers peni-
cillin-resistant isolates. However, the
addition of vancomycin is required for
adequate therapy for 3rd generation
cephalosporin-resistant isolates.
Because of the frequency of these
resistant isolates in the USA the
empirical therapy of meningitis in that
country includes vancomycin. This is
not currently recommended in South
Africa, although we are approaching
the time when such therapy may be
necessary. Surveillance data are
essential to guide such decisions.
Blood culture isolates
Penicillin resistance increased from
4.9% in 1979 to 14.1% in 1990 for
normally sterile site isolates from
patients presenting to the public sector
in South Africa.5 Currently 18% of
invasive isolates submitted to the
Respiratory and Meningeal Pathogens
Research Unit (RMPRU) are resistant to
penicillin (Table II). Small numbers of
isolates with high-level resistance to
penicillin were documented (4 of
2 127 tested (0.2%)). Approximately
Table I. Important components of surveillance systems to be
kept in mind when interpreting data
At laboratory level
Method of susceptibility testing: disc diffusion testing v. MIC determina-
tion with E tests or MIC determination with broth or agar dilutions
Antibiotics selected for testing
Quality assurance programmes within the laboratory 




Unique v. repeat isolates
Defined specimens, or all specimens included
Restricted organisms, or all organisms included  
Patient selection 
Community v. hospital population
Any clinical inclusion and exclusion criteria 
Adapted from Masterten RG. J Antimicrob Chemother 2000; 46: 53-58.2
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99 of 2 245 (4.4%) were cases
reported from the private sector.
Penicillin resistance has remained sta-
ble over the past 5 years.6 Of these
isolates, 9% were erythromycin resist-
ant.
Data from the private sector for blood
culture isolates in patients with proba-
ble lower respiratory tract infections
show intermediate resistance to 3rd
generation cephalosporins, ranging
from 0% to 25% between centres, with
no high-level resistance being docu-
mented in isolates (Adrian Brink and
the ASF — personal communication).
Erythromycin resistance of these iso-
lates ranges from 22% to 30%.
Sputum isolates
The role of sputum isolates in diagnos-
ing the aetiology of lower respiratory
tract infections is controversial.1
Pneumococcal isolation may not
always represent the true bacterial
causation of pneumonia, and unless
some effort is made to exclude coloni-
sation, these data may represent only
information about colonising pneumo-
cocci in a certain population.
Data from a recent study identified
high levels of resistance in pneumo-
cocci isolated from non-sterile site
specimens: 30% intermediate and
46% high-level resistance to
penicillin.7 However, 82% of these iso-
lates were submitted from one labora-
tory in Pretoria. Additional information
about patient characteristics and type
of specimen collected would make
these very important figures more help-
ful to clinicians, not only in Pretoria
but also in South Africa as a whole.
The Alexander Project received 83
pneumococcal isolates from South
Africa in 1996 and 66 in 1997.
Intermediate resistance to penicillin
was quoted as 31% and 26% respec-
tively, and high-level resistance as 4%
and 4.5%.8 These isolates were from a
referral laboratory, which may have
led to the biased results.
There is wide variation in susceptibility
data for pneumococcal isolates from
non-sterile sites. This may be due to a
number of factors and additional stud-
ies are needed to determine rates of
resistance accurately.
Haemophilus influenzae
The proportion of sterile site isolates of
Haemophilus influenzae producing
beta-lactamase and submitted to the
surveillance laboratory since 1999
remains constant (Table III).
Beta-lactamase production from H.
influenzae sputum isolates is document-
ed at 7% in some South African studies.7, 8
Although not clearly stated, most of
these isolates would be non-typeable
H. influenzae, as non-typeable strains
are more commonly described in
lower respiratory tract infections with-
out bacteraemia.
Neisseria meningitidis
Increasing MICs of Neisseria meningi-
tidis have been documented in South
Africa and elsewhere in the world,
although the clinical significance of
disease caused by these isolates is
unknown. Currently penicillin remains
the drug of choice for treatment of
invasive disease. Ongoing surveil-
lance remains important.
Salmonella spp.
The Enteric Diseases Reference Unit
(EDRU) has received a number of mul-
tidrug-resistant Salmonella isolates
from hospitals in South Africa during
the past 2 years. These isolates are
predominantly S. enterica serovar
Typhimurium and S. enterica serovar
Isangi. Many of the S. typhimurium
and all the S. serovar Isangi strains
express an extended spectrum beta-
lactamase (ESBL). These isolates com-
prise approximately 50% and 20%
respectively of all isolates received at
EDRU (approximately 500 isolates
each year). Nalidixic acid resistance
in S. serovar Isangi has increased from
25% to 70% in isolates received in the
past 6 months (K H Keddy — personal
communication).
ESBL-producing organisms were classi-
cally Klebsiella sp., and are often
associated with nosocomial infection.
The above-mentioned Salmonella sp.
Table II. Antimicrobial resistance in invasive pneumococcal isolates sent to RMPRU, NICD
(August 2001 - July 2002)
No. and % of resistant isolates   
< 5 yrs ≥ 5 yrs Age unknown Total  
(N = 746) (N =1 095) (N = 286, 2 not tested)(N = 2 127, 2 not tested)
Antibiotic No. % No. % No. % No. %  
Penicillin         
Intermediately resistant* 212 28 131 12 48 17 391 18  
Fully resistant† 2 0.3 2 0.2 0 0 4 0.2  
Trimethoprim/
sulphamethoxazole 433 58 320 29 89 31 842 40  
Cefotaxime 0 0 0 0 0 0 0 0
*0.12 mg/l -1 mg/l.
†≥ 2 mg/l.
RMPRU = Respiratory and Meningeal Pathogens Research Unit; NICD = National Institute for Communicable Diseases.
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isolates (isolated from blood cultures
and stool) may also have been noso-
comial infections originally, especially
in paediatric wards. Recently patients
from the community, without any histo-
ry of previous hospital admissions,
have been presenting to both paedi-
atric and adult wards with these resist-
ant organisms.
Fluoroquinolone-susceptible strains of
Salmonella that test resistant to nalidix-
ic acid may be associated with clini-
cal failure or a delay in response to
therapy in fluoroquinolone-treated
patients with extra-intestinal salmonel-
losis. This may need to be considered
when treating patients with bacter-
aemia due to the Salmonellae men-
tioned above. 
Vibrio cholerae
The current cholera epidemic is associ-
ated with a multidrug-resistant strain of
Vibrio cholerae El Tor Ogawa and V.
cholerae El Tor Inaba. The current
strains are resistant to ampicillin,
trimethoprim-sulphamethoxazole, tetra-
cycline (doxycycline) and erythromy-
cin. MICs for nalidixic acid are
increasing and recent isolates received
at the EDRU show intermediate resist-
ance to nalidixic acid (K H Keddy —
personal communication). Rehydration
of the patient remains the mainstay of
therapy.
CONCLUSIONS
Accurate surveillance of antimicrobial
susceptibility, taking into account local
needs, is important for the develop-
ment of rational empirical therapy
guidelines.
Some of the data detailed above
begin to answer these needs.
However, surveillance programmes
locally and nationally need to continue
to improve their efforts to assist the
fight against resistance. Increasing the
number of laboratories participating in
surveillance systems may improve the
accuracy of information.
In order for South Africa to answer
this need, both private and public
microbiology laboratories have come
together to form a surveillance group
(National Antimicrobial Surveillance
Forum (NASF) — funded by support
from pharmaceutical companies*) that
will collect data from as many labora-
tories as possible, and then present
these data regularly, with breakdown
relevant to clinicians in the private and
public sector.
Hopefully this initiative will lead to
improved patterns of antimicrobial
usage within South Africa.
* Pharmaceutical companies supporting NASF:
Abbott, Aspen, AstraZeneca, Aventis, Bayer, Bristol-
Myers Squibb, Sandoz (Novartis), GlaxoSmithKline,
Lilly, Merck, Sharpe & Dohme, Pfizer, Roche, and
Wyeth.
References available on request.
Antimicrobial susceptibility surveil-
lance plays an important role in
guiding empirical antimicrobial
therapy.
Interpreting such data needs to take
into consideration the method of
testing in the laboratory, the type of
specimen from which the organism
was isolated, and the type of
patient who was selected.
Between 15% and 20% of Strepto-
coccus pneumoniae causing menin-
gitis and bacteraemia in South
Africa are intermediately resistant
to penicillin (levels are higher in the
private sector).
High-level resistance to penicillin or
resistance to 3rd generation
cephalosporins is still uncommon,
especially in the public sector.
Multidrug-resistant Salmonella
species are being isolated through-
out the country.
Accurate antimicrobial susceptibility
data for all health care sectors
need to be a goal for laboratories
throughout the country.
IN A NUTSHELL
Table III. Beta-lactamase production of submitted Haemophilus spp. isolates
Year 1* Year 2* Year 3*  
Age N B/L + % N B/L + % N B/L + %  
Haemophilus
influenzae type b
< 5 yrs 109   14 of 108 tested 13 49 10 20 39 8 of 36 22   
≥ 5 yrs 15 1 7 28 6 21 14 1 of 13 8
Unknown 9 2 22 12 3 25 6 0 of 4 0
133 17 of 132 13 89 19 21 59 9 of 53 17
Haemophilus spp.
not type b
< 5 yrs 23 6 26 18 3 17 32 4 of 30 13
≥ 5 yrs 12 0 0 21 0 0 9 1 of 8 13
Unknown 6 1 17 5 1 20 4 0 of 3 0
41 7 17 44 4 9 45 5 of 41 12
B/L = Beta-lactamase-producing isolate.
*Year 1: July 1999 - July 2000; year 2: August 2000 - July 2001; year 3: July 2001 - August 2002.
